Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer

BACKGROUND: To report our findings on quality of life (QoL) in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel (q3w nab-PTX) in patients with metastatic breast cancer (MBC). METHODS: Patients with HER2-negative MBC were randomly assigned to three different do...

Descripción completa

Detalles Bibliográficos
Autores principales: Taira, Naruto, Kashiwabara, Kosuke, Tsurutani, Junji, Kitada, Masahiro, Takahashi, Masato, Kato, Hiroaki, Kikawa, Yuichiro, Sakata, Eiko, Naito, Yoichi, Hasegawa, Yoshie, Saito, Tsuyoshi, Iwasa, Tsutomu, Takashima, Tsutomu, Aihara, Tomohiko, Mukai, Hirofumi, Hara, Fumikata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421464/
https://www.ncbi.nlm.nih.gov/pubmed/34491513
http://dx.doi.org/10.1007/s12282-021-01290-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421464/
https://www.ncbi.nlm.nih.gov/pubmed/34491513
http://dx.doi.org/10.1007/s12282-021-01290-5

Ejemplares similares